Nothing Special   »   [go: up one dir, main page]

CY1108004T1 - Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb - Google Patents

Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb

Info

Publication number
CY1108004T1
CY1108004T1 CY20071100348T CY071100348T CY1108004T1 CY 1108004 T1 CY1108004 T1 CY 1108004T1 CY 20071100348 T CY20071100348 T CY 20071100348T CY 071100348 T CY071100348 T CY 071100348T CY 1108004 T1 CY1108004 T1 CY 1108004T1
Authority
CY
Cyprus
Prior art keywords
arylopropionic
medicines
humans
animals
patients
Prior art date
Application number
CY20071100348T
Other languages
English (en)
Inventor
Gerd Geisslinger
Kay Brune
Original Assignee
Paz Arzneimittel-Entwicklungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7898653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108004(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paz Arzneimittel-Entwicklungsgesellschaft Mbh filed Critical Paz Arzneimittel-Entwicklungsgesellschaft Mbh
Publication of CY1108004T1 publication Critical patent/CY1108004T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στη χρήση R-εναντιομερών αρυλοπροπιονικών οξέων ή παραγώγων αρυλοπροπιονικών οξέων για την παραγωγή φαρμάκων, τα οποία αναστέλλουν τον καταιγισμό ενεργοποίησης του NF-KB και επομένως είναι κατάλληλα για την αντιμετώπιση παθήσεων οι οποίες μπορούν να επηρεαστούν θετικά από θεραπευτικής άποψης μέσω της αναστολής του σχηματισμού του NF-KB.
CY20071100348T 1999-02-24 2007-03-13 Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb CY1108004T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19907895A DE19907895A1 (de) 1999-02-24 1999-02-24 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
EP00904922A EP1154766B1 (de) 1999-02-24 2000-01-17 Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können

Publications (1)

Publication Number Publication Date
CY1108004T1 true CY1108004T1 (el) 2013-09-04

Family

ID=7898653

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100348T CY1108004T1 (el) 1999-02-24 2007-03-13 Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb

Country Status (11)

Country Link
EP (1) EP1154766B1 (el)
JP (1) JP2002537325A (el)
AT (1) ATE350027T1 (el)
CA (1) CA2362888C (el)
CY (1) CY1108004T1 (el)
DE (2) DE19907895A1 (el)
DK (1) DK1154766T3 (el)
ES (1) ES2280196T3 (el)
PT (1) PT1154766E (el)
RU (1) RU2250103C2 (el)
WO (1) WO2000050019A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
ITMI20030312A1 (it) * 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
RU2532027C2 (ru) 2009-07-24 2014-10-27 Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки
GB2485169A (en) * 2010-11-03 2012-05-09 Univ Jw Goethe Frankfurt Main (R)-flurbiprofen for use in the treatment of multiple sclerosis
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
RU2457840C1 (ru) * 2011-03-09 2012-08-10 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Средство, воздействующее на активность некоторых ядерных факторов транскрипции
WO2014007780A1 (en) 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
WO2014007779A1 (en) 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
RU2675693C1 (ru) * 2017-11-16 2018-12-24 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ ингибирования нуклеарного фактора каппа В с использованием 5-гидроксиникотината калия в культуре клеток

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
DE19716713A1 (de) * 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
EP1143958B8 (en) * 1998-09-03 2007-05-23 Loma Linda University Medical Center Pharmaceutical composition and use of rnsaid for treating inflammation

Also Published As

Publication number Publication date
WO2000050019A2 (de) 2000-08-31
DE50013934D1 (de) 2007-02-15
DK1154766T3 (da) 2007-05-14
CA2362888C (en) 2009-02-24
ES2280196T3 (es) 2007-09-16
EP1154766A2 (de) 2001-11-21
PT1154766E (pt) 2007-03-30
ATE350027T1 (de) 2007-01-15
RU2250103C2 (ru) 2005-04-20
DE19907895A1 (de) 2000-11-16
JP2002537325A (ja) 2002-11-05
WO2000050019A3 (de) 2000-12-14
EP1154766B1 (de) 2007-01-03
CA2362888A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
CY1108004T1 (el) Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb
ATE493983T1 (de) Thalidomide und dexamethason für die behandlung von tumors
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
CY1112962T1 (el) 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
HUP9900950A2 (hu) Nikotin-származékok alkalmazása gyulladásos bélbetegségek kezelésére alkalmas gyógyászati készítmények előállítására
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ITRM20020014A1 (it) Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
TW200510308A (en) Isophthalic acid derivatives
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
AR039682A1 (es) Un medicamento para el tratamiento o prevencion del acne
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais
ES2176513T3 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de afecciones de las mucosas de dificil terapia.
EE200200128A (et) Dekstrasoksaani kasutamine, produkt ja meetod psoriaasi raviks mõeldud ravimi valmistamiseks
ATE302007T1 (de) Kombination von lumilysergol und riluzol für die vorbeugung und/oder behandlung von motoneuronalen erkrankungen
ES2127133B1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита